Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00667342 · OUTCOME

Mean Vp

A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma · Source last updated 2023-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
(unitless)
Interval / dispersion
Standard Deviation
Time frame
Baseline through Week 10

What was measured

The fractional blood plasma volume (Vp) was used to evaluate clinical outcomes. The average for the distribution across the whole region of interest (ROI) was calculated as a summary measure for each data set.

Analysis population: The number analyzed at each time point differed due to missing observations at some of the time points

Groups in this outcome

A: Localized Resectable Disease

Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.

C: Metastatic Tumors

Stratum C participants had metastatic tumors.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease31
C: Metastatic Tumors11

Reported measurements

Baseline

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease26
C: Metastatic Tumors9
Values in (unitless) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.00810.0024Not reportedNot reportedNot reported
C: Metastatic Tumors0.00940.0016Not reportedNot reportedNot reported
Day -2

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease21
C: Metastatic Tumors6
Values in (unitless) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.00670.0020Not reportedNot reportedNot reported
C: Metastatic Tumors0.00770.0022Not reportedNot reportedNot reported
Day 1

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease21
C: Metastatic Tumors6
Values in (unitless) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.00700.0027Not reportedNot reportedNot reported
C: Metastatic Tumors0.00950.0027Not reportedNot reportedNot reported
Day 5

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease24
C: Metastatic Tumors8
Values in (unitless) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.00660.0033Not reportedNot reportedNot reported
C: Metastatic Tumors0.00890.0029Not reportedNot reportedNot reported
Week 5

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease28
C: Metastatic Tumors11
Values in (unitless) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.00630.0029Not reportedNot reportedNot reported
C: Metastatic Tumors0.00690.0032Not reportedNot reportedNot reported
Week 10

Analysis denominator · Participants

GroupSource count
A: Localized Resectable Disease27
C: Metastatic Tumors11
Values in (unitless) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
A: Localized Resectable Disease0.00600.0044Not reportedNot reportedNot reported
C: Metastatic Tumors0.00550.0026Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    non Inferiority Comment
    The association between response and Vp at Week 10 was evaluated.
    non Inferiority Type
    OTHER
    p Value
    0.0573
    statistical Method
    Logistic Regression
Complete source fields
analyses
  1. group Ids
    1. OG000
    non Inferiority Comment
    The association between response and Vp at Week 10 was evaluated.
    non Inferiority Type
    OTHER
    p Value
    0.0573
    statistical Method
    Logistic Regression
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.0024
        value
        0.0081
      2. group Id
        OG001
        spread
        0.0016
        value
        0.0094
    denoms
    1. counts
      1. group Id
        OG000
        value
        26
      2. group Id
        OG001
        value
        9
      units
      Participants
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.0020
        value
        0.0067
      2. group Id
        OG001
        spread
        0.0022
        value
        0.0077
    denoms
    1. counts
      1. group Id
        OG000
        value
        21
      2. group Id
        OG001
        value
        6
      units
      Participants
    title
    Day -2
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.0027
        value
        0.0070
      2. group Id
        OG001
        spread
        0.0027
        value
        0.0095
    denoms
    1. counts
      1. group Id
        OG000
        value
        21
      2. group Id
        OG001
        value
        6
      units
      Participants
    title
    Day 1
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.0033
        value
        0.0066
      2. group Id
        OG001
        spread
        0.0029
        value
        0.0089
    denoms
    1. counts
      1. group Id
        OG000
        value
        24
      2. group Id
        OG001
        value
        8
      units
      Participants
    title
    Day 5
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.0029
        value
        0.0063
      2. group Id
        OG001
        spread
        0.0032
        value
        0.0069
    denoms
    1. counts
      1. group Id
        OG000
        value
        28
      2. group Id
        OG001
        value
        11
      units
      Participants
    title
    Week 5
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.0044
        value
        0.0060
      2. group Id
        OG001
        spread
        0.0026
        value
        0.0055
    denoms
    1. counts
      1. group Id
        OG000
        value
        27
      2. group Id
        OG001
        value
        11
      units
      Participants
    title
    Week 10
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    2. group Id
      OG001
      value
      11
    units
    Participants
description
The fractional blood plasma volume (Vp) was used to evaluate clinical outcomes. The average for the distribution across the whole region of interest (ROI) was calculated as a summary measure for each data set.
dispersion Type
Standard Deviation
groups
  1. description
    Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.
    id
    OG000
    title
    A: Localized Resectable Disease
  2. description
    Stratum C participants had metastatic tumors.
    id
    OG001
    title
    C: Metastatic Tumors
param Type
MEAN
population Description
The number analyzed at each time point differed due to missing observations at some of the time points
reporting Status
POSTED
time Frame
Baseline through Week 10
title
Mean Vp
type
SECONDARY
unit Of Measure
(unitless)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice